Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
88 hedge funds and large institutions have $835M invested in Intercept Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 15 closing their positions.
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
22% more funds holding
Funds holding: 72 → 88 (+16)
21% more capital invested
Capital invested by funds: $691M → $835M (+$145M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
+$37.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$15.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.5M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$6.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$24.1M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$18.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$13.6M |
| 4 |
PC
PointState Capital
New York
|
-$5.78M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$4.63M |
ICPT Hedge Fund Activity: Q4 2013 in Review
88 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2013, worth a combined $835M — up 21% from $691M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ICPT positions and 15 closed out — a net gain of 16 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was SAC Capital Advisors, adding an estimated $37.4M. The largest seller was OrbiMed, cutting an estimated $24.1M.
- 88 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2013, up from 72 in Q3 2013.
- Funds reported $835M of Intercept Pharmaceuticals, Inc. stock for Q4 2013, up 21% quarter-over-quarter.
- 31 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2013 and 15 closed out, a net change of +16 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2013 was SAC Capital Advisors, an estimated $37.4M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2013 was OrbiMed, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2013.